More Than Half of Patients Experience Tumor Shrinkage! Clinical Data Unveiled for a Potential “First-in-Class” Therapy

Introduction to the Phase 2 Clinical Trial of Invikafusp Alfa

Marengo Therapeutics has recently revealed new clinical data from their ongoing Phase 2 trial assessing invikafusp alfa, a novel immunotherapy agent targeting advanced solid tumors. As of July 29, 2025, the trial enrolled 55 patients harboring tumors characterized by either high tumor mutational burden (TMB-H) or microsatellite instability-high (MSI-H) and mismatch repair deficiency (dMMR). These tumors spanned 21 distinct cancer types. Of these, 44 patients were evaluable for efficacy based on response criteria.

Clinical Efficacy Highlights

The study results are encouraging: over half (52%) of patients experienced measurable tumor shrinkage at target lesions. Specifically, among patients with TMB-H tumors, the overall response rate (ORR) was 20.5%, with a disease control rate (DCR) — reflecting patients achieving stable disease or better — reaching 79.5%. This subgroup represented a broad tumor spectrum including colorectal, gastric, lung, breast, gastroesophageal junction, and head and neck cancers.

For the MSI-H/dMMR cohort, responses appeared even more pronounced with an ORR of 30% and DCR of 70%. Notably, invikafusp alfa showed clinical activity in patients whose tumors were resistant or had recurred after PD-1 inhibitor therapy as well as those who had received atypical PD-1 treatments. This suggests that invikafusp alfa’s anti-tumor effects operate independently of the PD-1 signaling axis.

Safety Profile

Regarding safety, treatment-related adverse events were generally manageable and consistent with the drug’s mechanism of selectively activating T cells. No unexpected toxicities were reported, supporting the therapeutic approach’s tolerability in this patient population.

Mechanism of Action of Invikafusp Alfa

Invikafusp alfa is a pioneering “first-in-class” bispecific T cell agonist that selectively targets and activates the Vβ6 and Vβ10 subsets of T cells. These T cell populations comprise about 10% of tumor-infiltrating lymphocytes (TILs), which play a critical role in the body’s immune response against tumor cells.

By activating and expanding these specific T cell subsets, invikafusp alfa enhances the immune system’s ability to recognize and attack cancer cells. This dual agonist effect restores and amplifies antitumor immunity, offering a therapeutic avenue especially relevant for patients who have shown resistance or no response to established immune checkpoint inhibitors.

Clinical Significance and Future Directions

The efficacy of invikafusp alfa in heavily pretreated patients, including those with PD-1 refractory tumors, represents an important clinical advance. It suggests a potential new class of immunotherapy that can complement or overcome limitations of current checkpoint blockade therapies.

Marengo Therapeutics plans to further develop invikafusp alfa, including larger-scale studies to confirm these findings and explore its efficacy across different tumor types. If future trials confirm these promising results, invikafusp alfa could provide a much-needed option for patients with limited treatment alternatives.

Contextual Note on Related Therapies

For comparison, other immunotherapies such as Roche’s giredestrant have recently demonstrated significant benefits in hormone receptor-positive advanced breast cancer settings, underscoring the rapidly evolving landscape of cancer immunotherapy.

Conclusion

The initial clinical data for invikafusp alfa highlight its potential as a novel immunotherapeutic agent capable of inducing tumor regression and disease control in diverse, advanced solid tumors marked by high mutation burden or MSI-H/dMMR. Its unique mechanism of selectively activating key T cell subsets independent of PD-1 pathways makes it a promising candidate for patients with limited responses to existing immunotherapies. Ongoing research will clarify its role in the future oncology treatment landscape.

References

Roche’s Phase III evERA study data demonstrating giredestrant’s efficacy in ER-positive advanced breast cancer. Retrieved October 18, 2025, from https://www.roche.com/media/releases/med-cor-2025-10-18